#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0011] EP 349 188 describes a method for separating blood into blood components, and a separator unit for recovering these blood components.
1-1	0-1	[	_	_	
1-2	1-5	0011	_	_	
1-3	5-6	]	_	_	
1-4	7-9	EP	_	_	
1-5	10-13	349	_	_	
1-6	14-17	188	_	_	
1-7	18-27	describes	_	_	
1-8	28-29	a	*[1]	2-3[2_1]	
1-9	30-36	method	*[1]	_	
1-10	37-40	for	*[1]	_	
1-11	41-51	separating	*[1]	_	
1-12	52-57	blood	*[1]	_	
1-13	58-62	into	*[1]	_	
1-14	63-68	blood	*[1]	_	
1-15	69-79	components	*[1]	_	
1-16	79-80	,	_	_	
1-17	81-84	and	_	_	
1-18	85-86	a	_	_	
1-19	87-96	separator	_	_	
1-20	97-101	unit	_	_	
1-21	102-105	for	_	_	
1-22	106-116	recovering	_	_	
1-23	117-122	these	_	_	
1-24	123-128	blood	_	_	
1-25	129-139	components	_	_	
1-26	139-140	.	_	_	

#Text=According to this method, blood is first conveyed from a whole-blood container through a filter which removes leukocytes and also blood platelets.
2-1	141-150	According	_	_	
2-2	151-153	to	_	_	
2-3	154-158	this	*[2]	_	
2-4	159-165	method	*[2]	_	
2-5	165-166	,	_	_	
2-6	167-172	blood	_	_	
2-7	173-175	is	_	_	
2-8	176-181	first	_	_	
2-9	182-190	conveyed	_	_	
2-10	191-195	from	_	_	
2-11	196-197	a	_	_	
2-12	198-209	whole-blood	_	_	
2-13	210-219	container	_	_	
2-14	220-227	through	_	_	
2-15	228-229	a	_	_	
2-16	230-236	filter	_	_	
2-17	237-242	which	_	_	
2-18	243-250	removes	_	_	
2-19	251-261	leukocytes	_	_	
2-20	262-265	and	_	_	
2-21	266-270	also	_	_	
2-22	271-276	blood	_	_	
2-23	277-286	platelets	_	_	
2-24	286-287	.	_	_	

#Text=The filtered blood is then collected in a primary bag which is then subjected to centrifugation to divide the blood up into a plasma fraction and an erythrocyte concentrate.
3-1	288-291	The	_	_	
3-2	292-300	filtered	_	_	
3-3	301-306	blood	_	_	
3-4	307-309	is	_	_	
3-5	310-314	then	_	_	
3-6	315-324	collected	_	_	
3-7	325-327	in	_	_	
3-8	328-329	a	_	_	
3-9	330-337	primary	_	_	
3-10	338-341	bag	_	_	
3-11	342-347	which	_	_	
3-12	348-350	is	_	_	
3-13	351-355	then	_	_	
3-14	356-365	subjected	_	_	
3-15	366-368	to	_	_	
3-16	369-383	centrifugation	_	_	
3-17	384-386	to	_	_	
3-18	387-393	divide	_	_	
3-19	394-397	the	_	_	
3-20	398-403	blood	_	_	
3-21	404-406	up	_	_	
3-22	407-411	into	_	_	
3-23	412-413	a	_	_	
3-24	414-420	plasma	_	_	
3-25	421-429	fraction	_	_	
3-26	430-433	and	_	_	
3-27	434-436	an	_	_	
3-28	437-448	erythrocyte	_	_	
3-29	449-460	concentrate	_	_	
3-30	460-461	.	_	_	

#Text=The plasma is conveyed through a plasma line into a further plasma bag.
#Text=[0012] As has already been explained above, this method is technically complex because of the use of a centrifuge.
4-1	462-465	The	*[3]	4-25[4_3]	
4-2	466-472	plasma	*[3]	_	
4-3	473-475	is	*[3]	_	
4-4	476-484	conveyed	*[3]	_	
4-5	485-492	through	*[3]	_	
4-6	493-494	a	*[3]	_	
4-7	495-501	plasma	*[3]	_	
4-8	502-506	line	*[3]	_	
4-9	507-511	into	*[3]	_	
4-10	512-513	a	*[3]	_	
4-11	514-521	further	*[3]	_	
4-12	522-528	plasma	*[3]	_	
4-13	529-532	bag	*[3]	_	
4-14	532-533	.	*[3]	_	
4-15	534-535	[	_	_	
4-16	535-539	0012	_	_	
4-17	539-540	]	_	_	
4-18	541-543	As	_	_	
4-19	544-547	has	_	_	
4-20	548-555	already	_	_	
4-21	556-560	been	_	_	
4-22	561-570	explained	_	_	
4-23	571-576	above	_	_	
4-24	576-577	,	_	_	
4-25	578-582	this	*[4]	_	
4-26	583-589	method	*[4]	_	
4-27	590-592	is	_	_	
4-28	593-604	technically	_	_	
4-29	605-612	complex	_	_	
4-30	613-620	because	_	_	
4-31	621-623	of	_	_	
4-32	624-627	the	_	_	
4-33	628-631	use	_	_	
4-34	632-634	of	_	_	
4-35	635-636	a	_	_	
4-36	637-647	centrifuge	_	_	
4-37	647-648	.	_	_	

#Text=Moreover, the plasma cannot be separated completely, because there may otherwise be a danger of mixing with erythrocytes.
#Text=[0013] U.S.
5-1	649-657	Moreover	_	_	
5-2	657-658	,	_	_	
5-3	659-662	the	_	_	
5-4	663-669	plasma	_	_	
5-5	670-676	cannot	_	_	
5-6	677-679	be	_	_	
5-7	680-689	separated	_	_	
5-8	690-700	completely	_	_	
5-9	700-701	,	_	_	
5-10	702-709	because	_	_	
5-11	710-715	there	_	_	
5-12	716-719	may	_	_	
5-13	720-729	otherwise	_	_	
5-14	730-732	be	_	_	
5-15	733-734	a	_	_	
5-16	735-741	danger	_	_	
5-17	742-744	of	_	_	
5-18	745-751	mixing	_	_	
5-19	752-756	with	_	_	
5-20	757-769	erythrocytes	_	_	
5-21	769-770	.	_	_	
5-22	771-772	[	_	_	
5-23	772-776	0013	_	_	
5-24	776-777	]	_	_	
5-25	778-781	U.S	_	_	
5-26	781-782	.	_	_	

#Text=Pat.
6-1	783-786	Pat	_	_	
6-2	786-787	.	_	_	

#Text=No. 5,527,472 likewise describes a closed system for separation of whole-blood constituents by means of centrifugation.
7-1	788-790	No	*[5]	8-2[6_5]	
7-2	790-791	.	*[5]	_	
7-3	792-801	5,527,472	*[5]	_	
7-4	802-810	likewise	*[5]	_	
7-5	811-820	describes	*[5]	_	
7-6	821-822	a	*[5]	_	
7-7	823-829	closed	*[5]	_	
7-8	830-836	system	*[5]	_	
7-9	837-840	for	*[5]	_	
7-10	841-851	separation	*[5]	_	
7-11	852-854	of	*[5]	_	
7-12	855-866	whole-blood	*[5]	_	
7-13	867-879	constituents	*[5]	_	
7-14	880-882	by	*[5]	_	
7-15	883-888	means	*[5]	_	
7-16	889-891	of	*[5]	_	
7-17	892-906	centrifugation	*[5]	_	
7-18	906-907	.	*[5]	_	

#Text=In this method, the centrifugation initially takes place in a first bag with division into plasma and an erythrocyte concentrate, to which a substitute solution is then mixed.
8-1	908-910	In	_	_	
8-2	911-915	this	*[6]	_	
8-3	916-922	method	*[6]	_	
8-4	922-923	,	_	_	
8-5	924-927	the	_	_	
8-6	928-942	centrifugation	_	_	
8-7	943-952	initially	_	_	
8-8	953-958	takes	_	_	
8-9	959-964	place	_	_	
8-10	965-967	in	_	_	
8-11	968-969	a	_	_	
8-12	970-975	first	_	_	
8-13	976-979	bag	_	_	
8-14	980-984	with	_	_	
8-15	985-993	division	_	_	
8-16	994-998	into	_	_	
8-17	999-1005	plasma	_	_	
8-18	1006-1009	and	_	_	
8-19	1010-1012	an	_	_	
8-20	1013-1024	erythrocyte	_	_	
8-21	1025-1036	concentrate	_	_	
8-22	1036-1037	,	_	_	
8-23	1038-1040	to	_	_	
8-24	1041-1046	which	_	_	
8-25	1047-1048	a	_	_	
8-26	1049-1059	substitute	_	_	
8-27	1060-1068	solution	_	_	
8-28	1069-1071	is	_	_	
8-29	1072-1076	then	_	_	
8-30	1077-1082	mixed	_	_	
8-31	1082-1083	.	_	_	

#Text=This mixture is then freed of leukocytes in a leukocyte-removing filter, so that an erythrocyte concentrate with substitute solution is obtained, but which still contains a high proportion of plasma.
#Text=[0014] This method too is technically complex, and a high proportion of blood plasma remains in the erythrocyte concentrate.
#Text=[0015] As a result of this, the object of the invention is to provide a technically simple method for separation of whole blood into an erythrocyte concentrate and a thrombocyte-containing plasma, in which as little plasma as possible remains in erythrocyte concentrate, and which method can be performed directly at the donor site, in particular without any delay after withdrawal.
9-1	1084-1088	This	*[7]	9-37[8_7]	
9-2	1089-1096	mixture	*[7]	_	
9-3	1097-1099	is	*[7]	_	
9-4	1100-1104	then	*[7]	_	
9-5	1105-1110	freed	*[7]	_	
9-6	1111-1113	of	*[7]	_	
9-7	1114-1124	leukocytes	*[7]	_	
9-8	1125-1127	in	*[7]	_	
9-9	1128-1129	a	*[7]	_	
9-10	1130-1148	leukocyte-removing	*[7]	_	
9-11	1149-1155	filter	*[7]	_	
9-12	1155-1156	,	*[7]	_	
9-13	1157-1159	so	*[7]	_	
9-14	1160-1164	that	*[7]	_	
9-15	1165-1167	an	*[7]	_	
9-16	1168-1179	erythrocyte	*[7]	_	
9-17	1180-1191	concentrate	*[7]	_	
9-18	1192-1196	with	*[7]	_	
9-19	1197-1207	substitute	*[7]	_	
9-20	1208-1216	solution	*[7]	_	
9-21	1217-1219	is	*[7]	_	
9-22	1220-1228	obtained	*[7]	_	
9-23	1228-1229	,	*[7]	_	
9-24	1230-1233	but	*[7]	_	
9-25	1234-1239	which	*[7]	_	
9-26	1240-1245	still	*[7]	_	
9-27	1246-1254	contains	*[7]	_	
9-28	1255-1256	a	*[7]	_	
9-29	1257-1261	high	*[7]	_	
9-30	1262-1272	proportion	*[7]	_	
9-31	1273-1275	of	*[7]	_	
9-32	1276-1282	plasma	*[7]	_	
9-33	1282-1283	.	*[7]	_	
9-34	1284-1285	[	_	_	
9-35	1285-1289	0014	_	_	
9-36	1289-1290	]	_	_	
9-37	1291-1295	This	*[8]	_	
9-38	1296-1302	method	*[8]	_	
9-39	1303-1306	too	_	_	
9-40	1307-1309	is	_	_	
9-41	1310-1321	technically	_	_	
9-42	1322-1329	complex	_	_	
9-43	1329-1330	,	_	_	
9-44	1331-1334	and	_	_	
9-45	1335-1336	a	_	_	
9-46	1337-1341	high	_	_	
9-47	1342-1352	proportion	_	_	
9-48	1353-1355	of	_	_	
9-49	1356-1361	blood	_	_	
9-50	1362-1368	plasma	_	_	
9-51	1369-1376	remains	_	_	
9-52	1377-1379	in	_	_	
9-53	1380-1383	the	_	_	
9-54	1384-1395	erythrocyte	_	_	
9-55	1396-1407	concentrate	_	_	
9-56	1407-1408	.	_	_	
9-57	1409-1410	[	_	_	
9-58	1410-1414	0015	_	_	
9-59	1414-1415	]	_	_	
9-60	1416-1418	As	_	_	
9-61	1419-1420	a	_	_	
9-62	1421-1427	result	_	_	
9-63	1428-1430	of	_	_	
9-64	1431-1435	this	_	_	
9-65	1435-1436	,	_	_	
9-66	1437-1440	the	_	_	
9-67	1441-1447	object	_	_	
9-68	1448-1450	of	_	_	
9-69	1451-1454	the	_	_	
9-70	1455-1464	invention	_	_	
9-71	1465-1467	is	_	_	
9-72	1468-1470	to	_	_	
9-73	1471-1478	provide	_	_	
9-74	1479-1480	a	_	_	
9-75	1481-1492	technically	_	_	
9-76	1493-1499	simple	_	_	
9-77	1500-1506	method	_	_	
9-78	1507-1510	for	_	_	
9-79	1511-1521	separation	_	_	
9-80	1522-1524	of	_	_	
9-81	1525-1530	whole	_	_	
9-82	1531-1536	blood	_	_	
9-83	1537-1541	into	_	_	
9-84	1542-1544	an	_	_	
9-85	1545-1556	erythrocyte	_	_	
9-86	1557-1568	concentrate	_	_	
9-87	1569-1572	and	_	_	
9-88	1573-1574	a	_	_	
9-89	1575-1597	thrombocyte-containing	_	_	
9-90	1598-1604	plasma	_	_	
9-91	1604-1605	,	_	_	
9-92	1606-1608	in	_	_	
9-93	1609-1614	which	_	_	
9-94	1615-1617	as	_	_	
9-95	1618-1624	little	_	_	
9-96	1625-1631	plasma	_	_	
9-97	1632-1634	as	_	_	
9-98	1635-1643	possible	_	_	
9-99	1644-1651	remains	_	_	
9-100	1652-1654	in	_	_	
9-101	1655-1666	erythrocyte	_	_	
9-102	1667-1678	concentrate	_	_	
9-103	1678-1679	,	_	_	
9-104	1680-1683	and	_	_	
9-105	1684-1689	which	_	_	
9-106	1690-1696	method	_	_	
9-107	1697-1700	can	_	_	
9-108	1701-1703	be	_	_	
9-109	1704-1713	performed	_	_	
9-110	1714-1722	directly	_	_	
9-111	1723-1725	at	_	_	
9-112	1726-1729	the	_	_	
9-113	1730-1735	donor	_	_	
9-114	1736-1740	site	_	_	
9-115	1740-1741	,	_	_	
9-116	1742-1744	in	_	_	
9-117	1745-1755	particular	_	_	
9-118	1756-1763	without	_	_	
9-119	1764-1767	any	_	_	
9-120	1768-1773	delay	_	_	
9-121	1774-1779	after	_	_	
9-122	1780-1790	withdrawal	_	_	
9-123	1790-1791	.	_	_	
